Three-year Results of a Pilot Program in Early Liver Transplantation for Severe Alcoholic Hepatitis.
Brian P Lee, Po-Hung Chen, Christine Haugen...
https://pubmed.ncbi.nlm.nih.gov/27280501/Actively Recruiting
Led by Johns Hopkins University · Updated on 2026-06-09
200
Participants Needed
1
Research Sites
N/A
Total Duration
This research evaluates alcohol treatment outcomes after early versus standard liver transplantation for severe alcoholic hepatitis SAH. The trial aims to compare integrated, person- and computer-delivered alcohol treatment with standard care, focusing on alcohol use, mood, quality of life, and survival. It also explores predictors of alcohol use outcomes 12 months after transplantation to improve future treatment targeting for patients with alcoholic liver disease. Participants are assigned to either an integrated alcohol use disorder AUD treatment or treatment as usual. The integrated treatment includes computer-delivered brief intervention in the hospital, nurse-led alcohol monitoring counseling during outpatient follow-ups, and at-home web-based cognitive-behavioral therapy sessions supplemented by tailored text messages. All patients receive physician instructions to abstain from alcohol and standard post-transplant monitoring, including regular blood tests and phone follow-ups. During the study, participants will be regularly assessed for treatment engagement, alcohol relapse using both self-report and a biomarker PEth, mood, anxiety, and quality of life. The primary outcomes include engagement with follow-up appointments, time to alcohol relapse, and survival over one year. Researchers will monitor alcohol use through interviews and biomarker levels, as well as treatment adherence and retention in post-transplant care throughout the study duration.
CONDITIONS
Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH
M
MARY E MCCAUL, PhD
V
Victor Chen, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Johns Hopkins University
Lead Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Integrated Alcohol Use Disorder Treatment | Usual Care After Liver Transplant |
|---|---|---|
| What it is | A structured package combining computer-delivered brief intervention during hospital stay, personalized nurse counseling at transplant follow-up visits, and web-based cognitive behavioral therapy for alcohol use disorder with supportive text messaging. | Conventional post-liver transplant care for alcohol use disorder, without structured integrated behavioral and digital therapy features. |
| Role in the trial | Investigational intervention arm evaluating whether multi-component behavioral and digital therapies improve alcohol-related outcomes and post-transplant engagement. | Comparator arm representing the standard approach to alcohol use disorder management after liver transplantation. |
| Primary use or clinical purpose | To support alcohol use disorder remission, reduce relapse, and improve post-transplant survival through combined behavioral, digital, and nurse counseling interventions. | To manage alcohol use disorder and monitor transplant follow-up outcomes without added digital or structured behavioral therapies. |
| How it is given or performed | Computer-delivered brief intervention at hospital discharge, nurse counseling at outpatient follow-up visits, and web-based CBT accessed from home, supported by tailored text reminders. | Care as typically provided after liver transplant, including clinical monitoring and basic alcohol use disorder follow-up; no structured digital or behavioral additions. |
| Evidence status | Computerized CBT and brief intervention components have been shown to reduce alcohol use in clinical studies, but combined multi-component delivery in post-transplant populations is still under investigation; this trial will provide outcome evidence for the integrated approach. | Usual care effectiveness varies; alcohol use relapse monitoring after transplant is routine, but structured behavioral digital therapy is not typically included. Evidence for computer-based and nurse-delivered interventions supports potential benefit beyond standard care. |
| Important limitations | While individual components like CBT4CBT and brief intervention are supported externally, the multi-component approach in post-liver transplant populations lacks published long-term outcome data. The trial does not address medical contraindications or psychiatric instability as barriers for some patients. | Usual care does not include structured digital behavioral therapies and may have limited engagement or monitoring; relapse detection methods and post-transplant outcomes are variable across settings. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Brian P Lee, Po-Hung Chen, Christine Haugen...
https://pubmed.ncbi.nlm.nih.gov/27280501/Sharon R Weeks, Zhaoli Sun, Mary E McCaul...
https://pubmed.ncbi.nlm.nih.gov/29409981/Geetanjali Chander, Heidi E Hutton, Bryan Lau...
https://pubmed.ncbi.nlm.nih.gov/25967270/Michael Francis Fleming, Matthew J Smith, Erika Oslakovic...
https://pubmed.ncbi.nlm.nih.gov/28196282/Brian D Kiluk, Kathleen A Devore, Matthew B Buck...
https://pubmed.ncbi.nlm.nih.gov/27488212/Johns Hopkins University
Lead Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborating Sponsor